"Understanding the root cause of depression and new advances in treatment is of the utmost importance in order to offer the most effective treatment," - Andrew Farah, MD, Chief of Psychiatry, UNC, High Point Regional Health Systems.
Sunset, LA (PRWEB) June 24, 2014
The makers of the advanced folate prescription therapy, EnLyte, announced today that they are collaborating with University of North Carolina for a CME opportunity that will be available to all segments of the medical community.
"Homocysteine, Folates, and New Advances in Depression Therapy" is a brief presentation by Andrew Farah, MD, Chief of Psychiatry, UNC, High Point Regional Health Systems and expert on folate therapy use in Psychiatry. It will be available at http://www.EnLyteRx.Com, worth 2 CME credits, and downloadable in many formats, making it easy to participate. The company expects it to be available in the next couple of months, and will advertise it as soon as it's available. "Understanding the root cause of depression and new advances in treatment is of the utmost importance in order to offer the most effective treatment," states Dr. Farah.
Depression is on the rise, and new treatment modalities are being called for by patients and providers. This educational opportunity will give new insight into the underlying causes of depression and new advances in treatment that offer better side effect and safety profiles, at a fraction of the cost.
About JayMac Pharmaceuticals
JayMac Pharmaceuticals, LLC is based in Sunset, Louisiana and is dedicated to being on the forefront of natural, effective, and safe treatment for conditions related to folate deficiency.
EnLyte is an advanced generation folate replacement therapy containing Delta Folate, critical cofactors, and soy-derived PS Gold Omega 3's. Learn more at http://www.EnLyteRx.Com.